Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Macosta
"Funny this, I add after P3 failure and I am an idiot."
Why did you buy further shares after a "P3 failure" knowing that in your eyes the share is dead after 20 years and all the other **** you come out with.
Yes you are an Idiot!!!
Jesus wept, mrcosts are you really that thick?
You added your £1/2million and since p3 you've been telling us how useless the company is, it didn't stop you adding more though.
Polygon have added and I've not read any criticism from them, implied or hearsay or even a teeny tiny hint that they think this is, for example, a dead stock.
If you can't understand why you are being criticised and polygon aren't, I'll try and help (lol!) you are an idiot because you hold shares in a what you describe as a dead stock, polygon hold shares in what you (NB not polygon, that bit is important) describe as a dead stock.
Your opinion counts for nothing as far anyone else's investment is concerned
The only stock you hold if any Mr C is as a day trader.
I only hope you’re better at that than you are at scaring investors, because you’re rubbish at doing that.
This might be one or Orgs sockpuppets.
Funny this, I add after P3 failure and I am an idiot.
Poly add after P3 failure and they clearly know something...
Crying like a girl? This company has raised c. £85m and added no value to the company since the collapse of P3. We are entitled to a rant. RM should be only a market stall in Peckham, he might have more luck there trying to flog interferon.
Look at his comments in 2006.
Synairgen's focus is on the under-served severe segments of asthma and COPD. With the addition of COPD to our interferon programme, we now have two distinct indications where successful drugs could achieve annual sales in excess of $1 billion
- Add Covid into the interferon programme, he would have say we could achieve sales in excess of $2 billion.
What is SNG's current turnover?
Yes MR C
You missed when it was 18p and Polygon increased there holding by multiple millions
Strange for a dead stock?
Please keep up and try harder
Macosta everyone knows you are full of ****.
Constantly crying like a little girl but still claiming to hold £500k in shares.
Nobody with a sane mind would constantly talk this share down if they held so many shares. How would that be logical behaviour?
Give up all the bull**** you are making yourself look very silly now.
Mr Costly, I never referred to you as a “deramper” but it is good that you acknowledge what you most likely are. A trader with very limited ideas of how to influence investors and the owner of a happy shiny new British Airways Org that is applauding you from another forum.
SP 26p - have I missed something here?
Manifesto - they way you talk, the SP should be £10 a share.
The way I talk, the SP should be 26p, oh wait a second....
I've sent my prize carrier pigeon to Poly's headquarters to inform them
that this stock is offically "dead".... Mr.Cooooosts said so...
Just waiting or the RNS to say they have sold so I know they got the message...... : ))
“ The show is over, no one is talking about Synairgen”
Lmao - You and your merry band of trolls do nothing but talk about Synairgen.
You should start a support group “trolls anonymous”
mrcosts - "Anyone who invested during the height of covid fits in to the #barmpotinvestingstrategy."
What a stupid statement!
Investors saw a 700% rise at "the height of covid".
If you got your timing wrong then that is bad luck, it happens. What sets you apart is you actually told us you think this is a 'dead stock" yet you still hold over £500k worth of dead stock!
If you truly believe this is a dead stock you would have sold and put what's left in the bank for 2% rather than <0%, otherwise you are a blithering idiot.
OOPS ...Forgot to add TO bid..... : 0
when there are more posts per hour than share trades......you know where its going
There are a number of posters trying too hard to convince us that
it's dead...no news of significance till 2023...bottom drawer......
They have sold and looking for the teens to buy back in...That
is why I get attacked so much for posting that news is close....
Wonder what will happen when news lands.........I think ACTIV2 will be first
followed by Peer Review, then news of a new P3 and LC results.....!
ANY DAY NOW....... :D
GLA!
Anyone who invested during the height of covid fits in to the #barmpotinvestingstrategy.
I have already said I have messed up however some people on here still think RM & Co will deliver, that is #barmpotthinking
The show is over, no one is talking about Synairgen.
“This is a dead stock.”
That’s a fairly concrete statement. Not “might be” a dead stock. It is.
So why not sell your shares before you lose £125k?
Gunto2022 - please tell me the benefits of sitting here and 'deramping' this company. If I can earn money by watching this share price fall every day then kindly let me know how I can do this.
This is a dead stock.
Big smiles and firm handshakes at the AGM, was it going to be any different?
Nothing beats a poster with 500k pretend shares invested with the bonus ability to count the number of years.
New research signals second indication for Interferon beta programme in COPD 24 May 2006, Southampton, UK - Synairgen, the drug discovery company focused on the underlying causes of asthma and chronic obstructive pulmonary disease('COPD'), today announces new research signalling a second indication for its inhaled interferon beta ('IFN-beta') programme.
This new discovery is being presented today at the American Thoracic Society conference in San Diego, USA,the largest annual international conference of respiratory physicians. COPD, which is predominantly caused by smoking, is the fourth leading cause of death worldwide and is an area of significant unmet clinical need. Its total annual economic cost to the United States exceeds $35 billion, twice the cost of asthma. It is forecast that the global market for COPD drugs will double to $10billion per annum over the next five years. The common cold (Rhinovirus) is a major factor behind the worsening of COPD symptoms and result of many hospitalisations.
Preliminary data presented by Synairgen today, derived from its in vitro models of airway cells from smokers, indicates that these are unusually susceptible to the common cold virus and that the addition of IFN-beta improves their natural defence system. This suggests that IFN-beta treatment has the potential to reduce the likelihood of hospitalisation of COPD patients as a consequence of common cold infections. Following this discovery, Synairgen will utilise its in vitro models of COPD to further validate this target. The Company's inhaled IFN-beta programme for asthma is currently in Phase I trials. It is anticipated that the successful completion of these trials will help to accelerate clinical studies for this additional indication.
Richard Marsden, Managing Director of Synairgen, said, "Pharmaceutical and biotechnology companies are increasingly focusing on speciality drugs that address specific patient types which are under-treated within large disease areas.
Synairgen's focus is on the under-served severe segments of asthma and COPD. With the addition of COPD to our interferon programme, we now have two distinct indications where successful drugs could achieve annual sales in excess of $1 billion